Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : RETA crawled time : 13:00 save search
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
CNSP | News | $0.201 0.95% 120K
|
Health Technology
|
| O: -2.8%
H: 18.26%
C: 13.46%
rapid berubicin treatment ongoing glioblastoma study
Biogen Completes Acquisition of Reata Pharmaceuticals
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
BIIB | $193.99 -0.06% 660K
|
Health Technology
|
| O: -0.02%
H: 1.37%
C: 1.21%
acquisition pharmaceuticals
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.31%
H: 1.04%
C: 0.76%
CNSP | News | $0.201 0.95% 120K
|
Health Technology
|
| O: -2.46%
H: 2.53%
C: -10.61%
berubicin pharmaceuticals therapy results study
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
Published: 2023-03-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.96%
H: 1.07%
C: -1.66%
pharmaceuticals global conference
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.72%
H: 4.93%
C: 0.24%
CNSP | News | $0.201 0.95% 120K
|
Health Technology
|
| O: 5.88%
H: 15.28%
C: 11.0%
treatment ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Published: 2022-06-08 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.36%
H: 6.26%
C: 1.73%
CNSP | News | $0.201 0.95% 120K
|
Health Technology
|
| O: 0.98%
H: 3.23%
C: -0.9%
ongoing trial presentation berubicin potential designation
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.09%
H: 1.8%
C: 0.45%
CNSP | News | $0.201 0.95% 120K
|
Health Technology
|
| O: 5.16%
H: 7.69%
C: 6.16%
treatment approval berubicin potential glioblastoma
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Published: 2021-06-29 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.5%
H: 0.89%
C: -3.47%
CNSP | News | $0.201 0.95% 120K
|
Health Technology
|
| O: 33.33%
H: 0.0%
C: -20.52%
berubicin treatment fda fast track fast track designation granted grant designation glioblastoma
CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit
Published: 2021-05-11 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.54%
H: 3.11%
C: 0.54%
CNSP | News | $0.201 0.95% 120K
|
Health Technology
|
| O: -2.33%
H: 5.8%
C: 4.66%
presentation
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.